Document:

Form of Executive Officer Employment Agreement

 Exhibit 10.2 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement (“Agreement”) is entered
into as of the         day of
                                ,
         by and between
                                 (“Executive”) and Orexigen
Therapeutics, Inc. (the “Company”) and is contingent on final approval by the Company’s Board of Directors. 
 WHEREAS, the Company and Executive desire to amend and restate the Prior Agreement on the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto
as follows: 
 ARTICLE I 
 DEFINITIONS 
 For purposes of the Agreement, the following terms are defined as follows: 
 1.1 “Board” means the Board of Directors of the Company. 
 1.2 “Cause” means the occurrence of any of the following events: 
 (a) Executive’s conviction of or plea of guilty or nolo contendere to any felony or a crime of moral turpitude; 
 (b) Executive’s willful and continued failure or refusal to follow reasonable instructions of the Chief Executive Officer and/or President of the Company or reasonable policies,
standards and regulations of the Company or its affiliates; 
 (c) Executive’s willful and continued failure or
refusal to faithfully and diligently perform the usual, customary duties of her employment with the Company or its affiliates; 
 (d) Unprofessional, unethical, immoral or fraudulent conduct by Executive; 
 (e) Conduct by Executive
that materially discredits the Company or any affiliate or is materially detrimental to the reputation, character and standing of the Company or any affiliate; or 
 (f) Executive’s material breach of the Proprietary Information and Inventions Agreement. 
 An event described in Section 1.2(b) through Section 1.2(f) herein shall not be treated as “Cause” until after Executive has been given written notice of such event, failure or conduct and Executive fails to
cure such event, failure, conduct or breach, if curable, within 30 days from such written notice. Failure of the Company to meet financial or performance targets or goals shall not be deemed to be a breach pursuant to Sections 1.2(b) or 1.2(c)
herein. 
 1.3 “Change in Control” means the occurrence of any of the following events: 

 (a) the direct or indirect acquisition by any person or related group of persons
(other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more
than 50% of the total combined voting power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s shareholders which the Board does not recommend such shareholders to accept;

 (b) a change in the composition of the Board over a period of 36 months or less such that a majority of the Board
members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (i) have been Board members continuously since the beginning of such period, or (ii) have been elected or nominated for
election as Board members during such period by at least a majority of the Board members described in clause (i) who were still in office at the time such election or nomination was approved by the Board; 
 (c) the consummation of any consolidation, share exchange or merger of the Company (i) in which the stockholders of the Company
immediately prior to such transaction do not own at least a majority of the voting power of the entity which survives/results from that transaction (or the parent of such surviving/resulting entity), or (ii) in which a stockholder of the Company who
does not own a majority of the voting stock of the Company immediately prior to such transaction, owns a majority of the Company’s voting stock immediately after such transaction; or 
 (d) the liquidation or dissolution of the Company or any sale, lease, exchange or other transfer (in one transaction or a series
of related transactions) of all or substantially all the assets of the Company, including stock held in subsidiary corporations or interests held in subsidiary ventures. 
 1.4 “Company” means Orexigen Therapeutics, Inc. or, following a Change in Control, the surviving entity resulting from such transaction. 
 1.5 “Constructive Termination” means Executive’s Separation from Service as a result of Executive’s voluntary resignation following: 
 (a) a material reduction in the level of responsibility associated with Executive’s employment with the Company or any
surviving entity (other than a change in job title or officer title); 
 (b) any material reduction in
Executive’s level of base salary; or 
 (c) a relocation of Executive’s principal place of employment by
more than 50 miles (other than reasonable business travel required as part of the job duties associated with Executive’s position); 
 provided, and only in the event that, such change, reduction or relocation is effected by the Company without Cause and without Executive’s consent. 
  

 2 

 Executive must provide written notice to the Company of the occurrence of any of the
foregoing events or conditions without the Executive’s written consent within 90 days of the occurrence of such event. The Company or any surviving entity shall have a period of 30 days to cure such event or condition after receipt of written
notice of such event from Executive. Any Constructive Termination following such 30 day cure period must occur no later than the date that is two years following the initial occurrence of one of the foregoing events or conditions without
Executive’s written consent. Executive’s Constructive Termination shall be treated as involuntary. 
 1.6 “Covered
Termination” means an Involuntary Termination Without Cause or Constructive Termination that occurs within the one-month period before the effective date of a Change in Control and the six-month period commencing on the effective date of a
Change in Control. 
 1.7 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 1.8 “Involuntary Termination Without Cause” means Executive’s Separation from Service as a result of Executive’s
dismissal or discharge by the Company other than for Cause. The termination of Executive’s employment as a result of Executive’s death or disability will not be deemed to be an Involuntary Termination Without Cause. 
 ARTICLE II 
 EMPLOYMENT BY THE
COMPANY 
 2.1 Position and Duties. Subject to terms set forth herein, the Company agrees to employ Executive in the
position of                              and Executive hereby accepts such employment. Executive shall
serve in an executive capacity and shall perform such duties as are customarily associated with the position of
                             and such other duties as are assigned to Executive by the
                             of the Company. During the term of Executive’s employment with the
Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention (except for vacation periods and reasonable periods of illness or other incapacities permitted by the Company’s
general employment policies or as otherwise set forth in this Agreement) to the business of the Company. 
 2.2 Employment at
Will. Both the Company and Executive shall have the right to terminate Executive’s employment with the Company at any time, with or without Cause, upon 30 days’ written notice. If Executive’s employment with the Company is
terminated, Executive will be eligible to receive severance benefits to the extent provided in this Agreement. If applicable, upon the date of Executive’s termination of employment with the Company for any reason, Executive shall immediately
resign from the Board and the board of directors or comparable body of every subsidiary, parent or other affiliated corporation of the Company, and every committee thereof. 
 2.3 Employment Policies. The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including those
relating to protection of confidential information and assignment of inventions, except that when the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall
control. 
  

 3 

 2.4 Effective Date. The effective date of this agreement shall be the date in which Executive
begins employment with the Company which is anticipated to be                             .

 ARTICLE III 
 COMPENSATION AND BENEFITS 
 3.1 Base Salary. Executive
shall receive for services to be rendered hereunder an annual base salary of $                 (“Base Salary”), payable on the regular payroll
dates of the Company.1 
 3.2 Annual Bonus. In addition to the Base Salary, Executive will be eligible for an annual performance bonus, equal to up to 50% of the Base Salary, and which is 100% based upon the
achievement of the performance goals and objectives to be determined by the compensation committee of the Board (“Annual Bonus”). Such Annual Bonus shall be evaluated and paid no later than December 31 of the calendar year following
the calendar year to which such Annual Bonus relates.2 
 3.3 Stock Options. Subject to approval of the Board or the compensation committee of the Board, Executive shall receive stock options to purchase
                 shares of the Company’s common stock pursuant to the Company’s 2007 Equity Incentive Award Plan (the “2007 Plan”). Any stock
options granted pursuant to this Section 3.3 shall have an exercise price per share equal to the then-current fair market value per share of the Company’s common stock (as determined pursuant to the 2007 Plan) on the date the grant is approved
by the Board or the compensation committee of the Board. Such stock options shall be incentive stock options to the extent permitted under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). Subject to Section
4.2, 25% of the shares subject to such stock options shall vest on the one year anniversary of your date of hire and the remainder will vest in 36 equal monthly installments over a three year period thereafter, subject to Executive’s continued
employment or service with the Company on each such date. Such stock options shall have a ten (10) year term and shall be subject to the terms and conditions of the 2007 Plan and the stock option agreement pursuant to which such stock options are
granted to the extent such provisions are not less favorable to Executive than the applicable provisions of this Agreement. 
 3.4 Signing
Bonus. As of the date of this Agreement, Executive has received a signing bonus of $                 from the Company. Such signing bonus is subject to
repayment in the event Executive’s employment with the Company is terminated for any reason. Repayment of the signing bonus shall be forgiven by 50 percent on each of the first and second anniversaries of Executive’s commencement of
employment with the Company. 
  

	 1
	 Base salary level to be updated, as appropriate. 

	 2
	 Target bonus level to be updated, as appropriate.

  

 4 

 3.5 Vacation and Paid Time Off. Executive shall be entitled to 20 business days of paid vacation
each year, accruing on a monthly basis, 2 personal days, and 8 holidays each year. 
 3.6 Expenses. During the term of this Agreement,
the Company shall reimburse Executive for all reasonable and necessary out-of-pocket expenses incurred by Executive in connection with services rendered on behalf of the Company subject to Executive providing the Company with appropriate
substantiation in accordance with Company policy. Any amounts payable under this Section 3.5 shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive’s taxable year
following the taxable year in which Executive incurred the expenses. The amounts provided under this Section 3.5 during any taxable year of Executive’s will not affect such amounts provided in any other taxable year of Executive’s, and
Executive’s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. 
 3.7
Standard Company Benefits. Executive shall be entitled to all rights and benefits for which Executive is eligible under the terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to time
and are provided by the Company to its executive employees, employed at similar full-time or part-time status, as applicable, generally. 
 ARTICLE IV 
 SEVERANCE AND CHANGE IN CONTROL BENEFITS 
 4.1 Severance Benefits. In the event of Executive’s Separation from Service due to an Involuntary Termination Without Cause or a Covered Termination, Executive shall receive
any annual base salary that has accrued but is unpaid as of the date of such Involuntary Termination Without Cause or Covered Termination. In addition, subject to Section 4.3(a) below and Executive’s continued compliance with Articles V, VI and
VII below, Executive shall also be entitled to continue to be compensated by the Company, at Executive’s annual base salary rate as in effect during the last regularly scheduled payroll period immediately preceding the Involuntary Termination
Without Cause or Covered Termination, for a period of nine months, payable over such nine-month period on the regular payroll dates of the Company and subject to applicable tax withholding, beginning no later than the later of (a) sixty (60) days
following the date of the Executive’s Separation from Service or (b) sixty (60) days following the effective date of a Change in Control occurring within one-month following Executive’s Separation from Service. Notwithstanding any
provision to the contrary in this Agreement, no amount shall be paid pursuant to this Section 4.1 unless, on or prior to the fifty-fifth (55th) day following the date of the Executive’s Separation from Service, Executive has executed an
effective waiver and release of claims agreement (the “Release”) in form and substance acceptable to the Company and any applicable revocation period has expired. For purposes of Section 409A of the Internal Revenue Code of 1986, as
amended (the “Code”) (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), the Executive’s right to receive the foregoing installment payments shall be treated as a right to receive a series
of separate payments and, accordingly, each installment payment shall at all times be considered a separate and distinct payment. 
  

 5 

 4.2 Acceleration of Vesting of Option. In the event of a Change in Control, Executive shall
vest in and be able to exercise the stock options held by Executive as to 50% of the unvested shares of common stock then subject to such options. Thereafter, such options shall vest and become exercisable as to any unvested shares of common stock
subject to such options in equal monthly installments over the 12 months following the effective date of a Change in Control; provided, however, that in the event that fewer than 12 months remain until such options are fully vested and exercisable,
the vesting period for such options shall remain unchanged by the Change in Control. In addition, if within the period beginning on the first day of the calendar month immediately preceding the calendar month in which the effective date of such
Change in Control occurs and ending on the last day of the twelfth calendar month following the calendar month in which the effective date of the Change in Control occurs, Executive’s employment with the Company (or its successor) terminates
due to an Involuntary Termination Without Cause thereof by the Company (or any successor) or due to a Constructive Termination, then all stock options held by Executive shall become fully vested and exercisable as of the later of (a) the date of
such termination of Executive’s employment or (b) the date of the Change in Control. 
 4.3 Section 409A of the Internal
Revenue Code. 
 (a) Payment Delay. Notwithstanding anything herein to the contrary, to the extent any
payments to Executive pursuant to Section 4.1 are treated as non-qualified deferred compensation subject to Section 409A of the Code, then (i) no amount shall be payable pursuant to such section unless Executive’s termination of employment
constitutes a “separation from service” with the Company (as such term is defined in Treasury Regulation Section 1.409A-1(h) and any successor provision thereto) (a “Separation from Service”), and (ii) if Executive, at the time
of her Separation from Service, is determined by the Company to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code and the Company determines that delayed commencement of any portion of the termination benefits
payable to Executive pursuant to this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code (any such delayed commencement, a “Payment Delay”), then such portion of the
Executive’s termination benefits described in Section 4.1 shall not be provided to Executive prior to the earlier of (A) the expiration of the six-month period measured from the date of the Executive’s Separation from Service, (B) the date
of the Executive’s death or (C) such earlier date as is permitted under Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) deferral period, all payments deferred pursuant to a Payment Delay shall be paid in a lump
sum to Executive within 30 days following such expiration, and any remaining payments due under the Agreement shall be paid as otherwise provided herein. The determination of whether Executive is a “specified employee” for purposes of
Section 409A(a)(2)(B)(i) of the Code as of the time of her Separation from Service shall made by the Company in accordance with the terms of Section 409A of the Code and applicable guidance thereunder (including without limitation Treasury
Regulation Section 1.409A-1(i) and any successor provision thereto). 
 (b) Exceptions to Payment Delay.
Notwithstanding Section 4.3(a), to the maximum extent permitted by applicable law, amounts payable to Executive pursuant to Section 4.1 shall be made in reliance upon Treasury Regulation Section 1.409A-1(b)(9) (with respect to separation pay plans)
or Treasury Regulation Section 1.409A-1(b)(4) (with respect to short-term deferrals). Accordingly, the severance payments provided for in Section 4.1 are not intended to provide for any deferral of compensation subject 
  

 6 

 
to Section 409A of the Code to the extent (i) the severance payments payable pursuant to Section 4.1, by their terms and determined as of the date of
Executive’s Separation from Service, may not be made later than the 15th day of the third calendar month following the later of (A) the end of the Company’s fiscal year in which Executive’s Separation from Service occurs or (B) the
end of the calendar year in which Executive’s Separation from Service occurs, or (ii) (A) such severance payments do not exceed an amount equal to two times the lesser of (1) the amount of Executive’s annualized compensation based upon
Executive’s annual rate of pay for the calendar year immediately preceding the calendar year in which Executive’s Separation from Service occurs (adjusted for any increase during the calendar year in which such Separation from Service
occurs that would be expected to continue indefinitely had Executive remained employed with the Company) or (2) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) for the calendar year in which
Executive’s Separation from Service occurs, and (B) such severance payments shall be completed no later than December 31 of the second calendar year following the calendar year in which Executive’s Separation from Service occurs.

 (c) Interpretation. To the extent the payments and benefits under this Agreement are subject to Section 409A
of the Code, this Agreement shall be interpreted, construed and administered in a manner that satisfies the requirements of Sections 409A(a)(2), (3) and (4) of the Code and the Treasury Regulations thereunder (and any applicable transition relief
under Section 409A of the Code). As provided in Internal Revenue Notice 2007-86, notwithstanding any other provision of this Agreement, with respect to an election or amendment to change a time or form of payment under this Agreement made on or
after January 1, 2008 and on or before December 31, 2008, the election or amendment shall apply only with respect to payments that would not otherwise be payable in 2008, and shall not cause payments to be made in 2008 that would not otherwise be
payable in 2008. 
 4.4 Failure to Perform. Notwithstanding any other provision of this Agreement, if Executive shall be
discharged by the Company for Cause or if Executive terminates employment other than as a result of a Constructive Termination, then this Agreement shall automatically terminate (except for Article V, Article VII, and Article VIII, which shall
continue in effect), and upon such termination, the Company shall have no further obligation to Executive her spouse or estate, except that the Company shall pay to Executive, the amount of her base salary and vacation pay accrued to the date of
such termination. 
 ARTICLE V 
 PROPRIETARY INFORMATION OBLIGATIONS 
 5.1 Agreement. Executive agrees to execute and abide by the
Company’s standard form of Proprietary Information and Inventions Agreement (“Proprietary Information and Inventions Agreement”). 
 5.2 Remedies. Executive’s duties under the Proprietary Information and Inventions Agreement shall survive termination of Executive’s employment with the Company and the termination of this
Agreement. Executive acknowledges that a remedy at law for any breach or threatened breach by Executive of the provisions of the Proprietary Information and Inventions Agreement would be inadequate, and Executive therefore agrees that the Company
shall be entitled to injunctive relief in case of any such breach or threatened breach. 
  

 7 

 ARTICLE VI 
 OUTSIDE ACTIVITIES 
 6.1 Other Activities. Except with the prior written consent of the
Chief Executive Officer or President of the Company, Executive shall not during the term of this Agreement undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor;
provided that such passive investments will not require services on the part Executive which would in any manner impair the performance of her duties under this Agreement. Executive may engage in civic and not-for-profit activities so long as such
activities do not materially interfere with the performance of Executive’s duties hereunder. 
 6.2 Competition/Investments.
During the term of Executive’s employment by the Company, except on behalf of the Company, Executive shall not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant,
or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever which were known by Executive to compete
directly with the Company, throughout the world, in any line of business engaged in (or planned to be engaged in) by the Company. 
 ARTICLE VII 
 NONINTERFERENCE 
 While employed by the Company, and for one year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the
business of the Company by (i) soliciting or attempting to solicit any employee or consultant of the Company to terminate such employee’s or consultant’s employment or service in order to become an employee, consultant or independent
contractor to or for any competitor of the Company or (ii) soliciting or attempting to solicit any client, customer or other person either directly or indirectly, to direct her or its purchase of the Company’s products and/or services to any
person, firm, corporation, institution or other entity in competition with the business of the Company. Executive’s duties under this Article VII shall survive termination of Executive’s employment with the Company and the termination of
this Agreement. 
 ARTICLE VIII 
 GENERAL PROVISIONS 
 8.1 Notices. Any notices provided hereunder must be in writing and shall be deemed
effective upon the earlier of personal delivery (including personal delivery by facsimile) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive’s address as listed on
the Company payroll. 
  

 8 

 8.2 Severability. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality
or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained
herein. 
 8.3 Waiver. If either party should waive any breach of any provisions of this Agreement, they shall not thereby be
deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 
 8.4 Complete
Agreement. This Agreement and the documents and agreements referenced herein constitute the entire agreement between Executive and the Company and is the complete, final, and exclusive embodiment of their agreement with regard to the subject
matter contained herein and therein and supersede all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto, and
any prior agreement of the parties hereto in respect of the subject matter contained herein, including, without limitation, the Prior Agreement. This Agreement is entered into without reliance on any promise or representation other than those
expressly contained herein or therein, and cannot be modified or amended except in a writing signed by an appropriate officer of the Company and Executive. If Executive and the Company determine that any payments or benefits payable under this
Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem
reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code, the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. If any provision of
the Agreement would cause such payments or benefits to fail to so comply, such provision shall not be effective and shall be null and void with respect to such payments or benefits, and such provision shall otherwise remain in full force and effect.

 8.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of
more than one party, but all of which taken together will constitute one and the same Agreement. 
 8.6 Headings. The headings
of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 8.7 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except
that Executive may not assign any of Executive’s duties hereunder and Executive may not assign any of Executive’s rights hereunder, without the written consent of the Company, which shall not be withheld unreasonably. 
  

 9 

 8.8 Arbitration. Unless otherwise
prohibited by law or specified below, all disputes, claims and causes of action, in law or equity, arising from or relating to this Agreement or its enforcement, performance, breach, or interpretation shall be resolved solely and exclusively by
final and binding arbitration held in San Diego, California through Judicial Arbitration & Mediation Services/ Endispute (“JAMS”) under the then existing JAMS arbitration rules. However, nothing in this section is intended to
prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Each party in any such arbitration shall be responsible for its own attorneys’ fees, costs and necessary
disbursement; provided, however, that if one party refuses to arbitrate and the other party seeks to compel arbitration by court order, if such other party prevails, it shall be entitled to recover reasonable attorneys’ fees, costs and
necessary disbursements; provided, further, that the prevailing party shall be reimbursed for such fees, costs and expenses within 45 days following any such award, but in no event later than the last day of the Executive’s
taxable year following the taxable year in which the fees, costs and expenses were incurred; provided, further, that the parties’ obligations pursuant to this sentence shall terminate on the 10th anniversary of the date of Executive’s termination of employment. Pursuant to California Civil Code Section 1717, each party warrants that it was represented by counsel in the
negotiation and execution of this Agreement, including the attorneys’ fees provision herein. 
 8.9 Attorneys’ Fees.
If either party hereto brings any action to enforce rights hereunder, each party in any such action shall be responsible for its own attorneys’ fees and costs incurred in connection with such action. 
 8.10 Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of
the State of California without regard to the conflicts of law provisions thereof. 
 (Signature page follows) 
  

 10 

 IN WITNESS WHEREOF,
the parties have executed this Agreement on the day and year first above written. 
  

			
	OREXIGEN THERAPEUTICS, INC.
		
	 By:
	 	 
		 	 Eckard Weber, M.D.
 Interim President and
CEO

 Accepted and agreed: 
  
  
  
 NAME 
 11Naltrexone Hydrochloride Supply Agreement

 Exhibit 10.26 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 NALTREXONE HYDROCHLORIDE SUPPLY AGREEMENT 
 This
Naltrexone Hydrochloride Supply Agreement (this “Agreement”) is made as of this day of January 5, 2009 (the “Effective Date”) by and among OREXIGEN THERAPEUTICS, INC. (“OREXIGEN”), a
Delaware corporation located at 3344 N. Torrey Pines Court, Suite 200, La Jolla, CA 92037, and CILAG GMBH INTERNATIONAL (“CILAG”), a corporation of Switzerland located at Landis+Gyr-Strasse 1, 6300 Zug, Switzerland. 
 WHEREAS, CILAG is a manufacturer of Naltrexone Hydrochloride and wishes to manufacture and supply Naltrexone Hydrochloride to OREXIGEN on the terms described herein; and

 WHEREAS, OREXIGEN desires a supply of commercial quantities of Naltrexone Hydrochloride on the terms described herein. 
 NOW, THEREFORE, in consideration of the mutual covenants set forth herein, CILAG and OREXIGEN (each, a “Party” and, collectively, the
“Parties”) agree as follows. 
  

	1.	SCOPE OF AGREEMENT 

  

	1.1.	This Agreement shall apply to all purchases of Naltrexone Hydrochloride by OREXIGEN from CILAG during the term of this Agreement. 

  

	1.2.	This Agreement does not constitute a purchase order. Purchases under this Agreement shall be made only with purchase orders issued by OREXIGEN to CILAG (each, a “Purchase
Order”). Each Purchase Order shall set forth the information required by Section 3.3 and shall be in the form attached hereto as Appendix A. Purchase Order No. 1153 between the Parties dated January 2, 2008 shall be
deemed an accepted Purchase Order under and pursuant to the terms of this Agreement. All terms and conditions of the Purchase Orders shall apply, provided that in the event of a conflict or inconsistency between the terms of any Purchase Order,
order acknowledgement, invoice, shipping terms, packaging slip or other documentation, and the terms of this Agreement, the terms of this Agreement shall control and prevail and such additional or inconsistent terms are hereby expressly rejected,
unless such documentation specifically states that it overrides conflicting terms of this Agreement and is signed by each of the Parties. 

  

	1.3.	All Naltrexone Hydrochloride sold by CILAG to OREXIGEN will be manufactured by CILAG in accordance with the terms of this Agreement. 

	2.	MANUFACTURING; SPECIFICATIONS; QUALIFICATION OF SECOND SOURCE

  

	2.1.	CILAG shall manufacture the Naltrexone Hydrochloride supplied to OREXIGEN in accordance with (a) the specifications set forth on Schedule A attached hereto, and
(b) the specifications, methods, processes and procedures, including site of manufacture, set forth in CILAG’s drug master file (“DMF”) for Naltrexone Hydrochloride to be filed with the U.S. Food and Drug Administration
(“FDA”) pursuant to Section 2.3 (both (a) and (b), including any modifications approved in accordance with Section 2.2 collectively, the “Specifications”). If CILAG wishes to make any change to the
Specifications or manufacturing process (including, but not limited to, any change that could affect the purity, potency, identity and/or physical properties of the Naltrexone Hydrochloride or the site of its manufacture), it shall notify OREXIGEN
in writing in advance thereof and comply with the requirements of Section 2.2 prior to implementing such change. Such notification shall describe the proposed change in sufficient detail, including any corresponding increase or decrease in
manufacturing cost, so as to permit OREXIGEN to understand the reasons for the proposed change and to evaluate the impact of such change to oral formulations containing Naltrexone Hydrochloride (the “Finished Products”). OREXIGEN
may request from time to time that CILAG implement voluntary changes to the Specifications upon written request to CILAG. CILAG shall use commercially reasonably efforts to implement such request from OREXIGEN, which if carried out shall be at
OREXIGEN’s expense. In the event that a voluntary change to the Specifications is to be implemented, CILAG shall perform, at OREXIGEN’s expense, all analytical or experimental work in connection with making any such changes, but OREXIGEN
shall be responsible, at its expense, for filing all changes proposed by OREXIGEN in connection with any regulatory approval, and for seeking approval of any such change required by each applicable Regulatory Agency (as defined in Section 2.2).

  

	2.2.	Without limiting the generality of the foregoing provisions, CILAG shall not change the Specifications unless [***], each having jurisdiction over Naltrexone Hydrochloride, the
Finished Products or OREXIGEN’s marketing of Finished Products (each a “Regulatory Agency”). If any change to the Specifications requires the approval of a Regulatory Agency, such change [***]. To the extent [***]. For the
avoidance of doubt, CILAG shall not supply to OREXIGEN hereunder, and OREXIGEN shall have no obligation to accept, any Naltrexone Hydrochloride from CILAG manufactured in contravention of this Section 2.2. 

  

	2.3.	 CILAG will take commercially reasonable steps necessary to enable OREXIGEN to secure from the relevant Regulatory Agencies approval of CILAG and any applicable
Second-Source Supplier (as defined in Section 2.5) as a source of supply of Naltrexone Hydrochloride for OREXIGEN’s Finished Products to be marketed anywhere in the world. Without limiting the generality of the foregoing, CILAG will supply
to OREXIGEN sufficient quantities of Naltrexone Hydrochloride to enable OREXIGEN to support the filing of one or more New Drug Applications (the “NDA”) (or Abbreviated New Drug Application (“ANDA”), if applicable),
together with all amendments and supplements thereto, referencing CILAG or any applicable Second-Source Supplier as its supplier of Naltrexone Hydrochloride for its initial Finished Product candidate. CILAG will be responsible for procuring and
maintaining all regulatory filings and any other compliance efforts, including without limitation, 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	 
the DMF, related to Naltrexone Hydrochloride that are required in order to obtain approval from the FDA of OREXIGEN’s NDAs (or ANDAs, if applicable)
referencing Naltrexone Hydrochloride and equivalent approvals from Regulatory Agencies in other jurisdictions, at no additional cost to OREXIGEN. CILAG shall file the DMF with the FDA and shall provide the DMF’s reference number in writing to
OREXIGEN at least [***] ([***] days prior to Orexigen’s filing of an NDA (or ANDA, if applicable). OREXIGEN shall have the right to reference the DMF in its NDAs (or ANDAs, if applicable) and equivalent approvals from Regulatory Agencies in
jurisdictions outside the United States, and the right to access the open part of the DMF. [***]. 

  

	2.4.	CILAG shall test, or have tested, each lot of Naltrexone Hydrochloride shipped to OREXIGEN using the analytical testing methodologies which are set forth in the Specifications in
order to assure the conformity of each lot of Naltrexone Hydrochloride supplied hereunder to the Specifications and all Applicable Laws (as defined in Section 8.1.1). With each shipment of Naltrexone Hydrochloride, CILAG shall deliver to
OREXIGEN certificates of analysis from CILAG (a) stating that the Naltrexone Hydrochloride being shipped has been tested and does conform to the Specifications, (b) setting forth in detail the testing methodology employed by CILAG in
making the foregoing determination and the results generated by such tests, and (c) confirming compliance with the current good manufacturing practices (“cGMP”) required by the FDA, and other relevant Regulatory Agencies in
those jurisdictions of which OREXIGEN has given CILAG notice, with respect to the manufacture and testing of Naltrexone Hydrochloride for use as an active pharmaceutical ingredient in the Finished Products and subsequent sale in such jurisdictions.

  

	2.5.	CILAG shall have the option, at its sole cost and expense and subject to the terms and conditions of this Agreement, to qualify one second-source supplier for Naltrexone
Hydrochloride (“Second-Source Suppler”). CILAG shall provide at least [***] ([***]) months prior written notice of its intent to so qualify a Second-Source Supplier. CILAG shall not implement the use of such Second-Source Supplier
until (i) OREXIGEN has approved such Second-Source Supplier, which approval shall not be unreasonably withheld, including the conduct by OREXIGEN of an audit of the Second-Source Supplier, and (ii) OREXIGEN has received the requisite
approvals from all applicable Regulatory Agencies to use such Second-Source Supplier. 

  

	3.	FORECASTS; FIRM COMMITMENT; PURCHASE ORDERS 

  

	3.1.	 In order to assist CILAG in planning the production runs for Naltrexone Hydrochloride, beginning at least [***] ([***]) year prior to OREXIGEN’s anticipated
Commercial Launch (as defined in Section 3.2), OREXIGEN shall use its commercially reasonable efforts to provide to CILAG, prior to the beginning of each calendar quarter, a twelve (12) month rolling forecast of the quantities of
Naltrexone Hydrochloride required by OREXIGEN, by month, for the following twelve (12) month period (the “Rolling Forecast”). OREXIGEN may, at its discretion, update such Rolling Forecast more frequently. The first [***]
([***]) months of each Rolling Forecast shall constitute a binding order on CILAG and OREXIGEN for the quantities of 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	 
Naltrexone Hydrochloride specified therein (“Firm Commitment”), and the following [***] ([***]) months of the Rolling Forecast shall be
non-binding estimates and shall be used by CILAG for planning purposes only. CILAG shall be obligated to supply no less than [***] percent ([***]%) of the quantity of Naltrexone Hydrochloride ordered by OREXIGEN pursuant to any Purchase Order which
complies with Section 3.3. Further, CILAG agrees to use commercially reasonable efforts to deliver any quantities of Naltrexone Hydrochloride ordered by OREXIGEN which exceed OREXIGEN’s Rolling Forecast by not more than [***] percent
([***]%) or for which a delivery date of less than [***] ([***]) days from the date of such Purchase Order is requested by OREXIGEN. 

  

	3.2.	After the Finished Products have received approval for marketing from a Regulatory Agency and have been made generally commercially available (hereinafter “Commercial
Launch”), CILAG shall, within [***] ([***]) business days after OREXIGEN has provided its quarterly forecast, notify OREXIGEN in writing of any prospective problems CILAG might have with respect to supplying OREXIGEN’s forecasted order
quantities. Upon receipt of such notice, the Parties shall promptly discuss the inability to supply the amounts forecasted by OREXIGEN and work in good faith to agree upon revised forecast amounts. Failing agreement, OREXIGEN’s last submitted
forecast shall be deemed to be the new quarterly forecast. The foregoing notice and discussion requirements of this Section 3.2 shall not operate to relieve CILAG of its obligations pursuant to any Firm Commitment Purchase Order (as defined in
Section 3.3), or affect OREXIGEN’s right to pursue any remedies that may be available to it. 

  

	3.3.	Prior to the beginning of each calendar quarter, OREXIGEN shall submit a binding, non-cancelable Purchase Order for the most recent Firm Commitment portion of the Rolling Forecast
for such calendar quarter (“Firm Commitment Purchase Order”). Each Purchase Order shall specify the quantity of Naltrexone Hydrochloride ordered, the total Price (as defined in Section 5.2) for such quantities of Naltrexone
Hydrochloride calculated in accordance with Section 5 hereof, and the required delivery date and destination, consistent with the terms of this Agreement. OREXIGEN shall submit each Purchase Order to CILAG at least [***] ([***]) days in advance
of the delivery date requested in the Purchase Order. Within [***] ([***]) business days after the date that a Purchase Order is submitted, CILAG shall acknowledge receipt of OREXIGEN’s Purchase Order and confirm that the amounts of Naltrexone
Hydrochloride ordered in the Purchase Order will be timely supplied. For the avoidance of doubt, CILAG shall be obligated to accept any such Purchase Order which complies with this Section 3.3. Notwithstanding the foregoing, any failure by
CILAG to respond to a Purchase Order within such [***] ([***]) day period shall be deemed acceptance of such Purchase Order. 

  

	3.4.	 CILAG agrees to retain at least a rolling [***] ([***]) month safety stock of Naltrexone Hydrochloride or intermediates to be used for sale by OREXIGEN based on the
average monthly quantities in the Rolling Forecast. CILAG will promptly notify OREXIGEN if CILAG’s manufacturing capacity will be insufficient to fill a Purchase Order submitted by OREXIGEN, and CILAG agrees that OREXIGEN shall receive [***] of
CILAG based upon OREXIGEN’s Rolling Forecast for Naltrexone Hydrochloride for the applicable quarter. Such notice will include the expected duration of the shortage and its impact on the 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	 
supply of Naltrexone Hydrochloride to OREXIGEN. Such notification shall not operate to relieve CILAG of its obligations to deliver the ordered amounts of
Naltrexone Hydrochloride or affect OREXIGEN’s right to pursue any remedies that may be available to it. CILAG will use its best efforts to mitigate the impact on OREXIGEN of shortages or other constrained capacity. The obligations of CILAG to
maintain the safety stock specified herein shall commence as of the Commercial Launch. 

  

	3.5.	During any period during this Agreement in which CILAG, for any reason, including, without limitation, a force majeure as provided in Section 13.1, fails to deliver the
requisite quantities of Naltrexone Hydrochloride included within any Firm Commitment Purchase Order, within [***] ([***]) days after the date of delivery confirmed in writing by CILAG or if CILAG otherwise anticipates or notifies OREXIGEN that it
will be unable to make delivery of all or a portion of the ordered Naltrexone Hydrochloride within [***] ([***]) days after the confirmed date of delivery, then OREXIGEN may refuse such late shipment of Naltrexone Hydrochloride from CILAG and
purchase such quantities under such Firm Commitment Purchase Order through a substitute third party supplier. The quantity of Naltrexone Hydrochloride purchased from the substitute supplier due to CILAG’s failure to supply shall be treated as
if it were purchased from CILAG for purposes of determining the [***] in the table of Schedule B for subsequent purchase of Naltrexone Hydrochloride. In the event CILAG regains its ability to resume supplying hereunder, OREXIGEN’s right to
purchase Naltrexone Hydrochloride from the substitute supplier shall terminate immediately upon the delivery by CILAG to OREXIGEN of written notice thereof except in respect of orders already placed or obligated to be placed by OREXIGEN from the
substitute supplier. Notwithstanding CILAG’s reinstatement, if CILAG fails to timely meet its continuing manufacturing and supply obligations to OREXIGEN (consistent with all representations, warranties and covenants herein) on more than
[***] occasions during [***], then in addition to any termination rights hereunder, the Exclusivity Obligation (as defined in Section 5.1) shall be of no further force and effect with respect to OREXIGEN for [***] and [***], provided, however,
CILAG shall still be obligated to perform all of its obligations under this Agreement. 

  

	4.	DELIVERY 

  

	4.1.	Each Purchase Order shall specify the quantity of Naltrexone Hydrochloride ordered and the required delivery date and destination, consistent with the terms of this Agreement.
Deliveries must be made on normal business days of the designated facility unless otherwise coordinated. 

  

	4.2.	Subject to any written agreement between OREXIGEN and CILAG to the contrary, CILAG shall make all necessary shipping arrangements to OREXIGEN’s designated facility. Freight
terms shall be as set forth in Schedule C. Title of the Naltrexone Hydrochloride shall pass from CILAG to OREXIGEN upon receipt by OREXIGEN or its designated agents of such product at the location specified in the Purchase Order.

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	4.3.	CILAG shall deliver the complete order amounts on the delivery date specified in the Purchase Order. CILAG shall be responsible for coordinating the import/export of the Naltrexone
Hydrochloride to the United States and to OREXIGEN’s designated manufacturing facilities in a timely manner and in compliance with the Specifications and all Applicable Laws. CILAG shall notify OREXIGEN of the expected delivery date of the
order to enable receipt to be coordinated. 

  

	4.4.	Subject to clearance by customs and, if required, the FDA or other Regulatory Agency, the Naltrexone Hydrochloride shall be delivered to OREXIGEN’s designated facility in
CILAG’s normal packaging and documentation for Naltrexone Hydrochloride, including, without limitation, any such procedures as reflected in CILAG’s DMF, provided that such packaging and documentation shall meet the customs and regulatory
requirements within the United States and/or Canada, as applicable, to the location of OREXIGEN’s designated facility for delivery. Each shipment shall include certificates of analysis, which include, without limitation, a statement of
compliance with cGMP, and such other documentation and information as may be necessary or desirable for complying with import, export and customs laws, regulations and requirements as applicable. 

  

	5.	EXCLUSIVITY; PRICE; PAYMENT 

  

	 5.1.
	 From a period beginning on the first December 31st following marketing approval by the FDA for a Finished Product (the “Qualification Date”) and continuing though the term of this Agreement, OREXIGEN agrees to
purchase from CILAG [***] percent ([***]%) of its requirements for Naltrexone Hydrochloride intended for commercial sale in Finished Products (the “Exclusivity Obligation”), provided that the Exclusivity Obligation shall not be
binding on OREXIGEN (a) in the event of breach by CILAG of any of the terms set forth herein which breach is not cured within the period set forth in Section 11.2 or (b) under the circumstances set forth in Section 3.5. [***].

  

	5.2.	The price for the Naltrexone Hydrochloride to be purchased by OREXIGEN hereunder is set forth in Schedule B, as adjusted in accordance with this Section 5 (the
“Price”). 

  

	5.3.	 The Price shall remain fixed for the first [***] ([***]) months of the Agreement, and thereafter shall be adjusted in accordance with this Section 5.3 on [***]
to take effect for orders to be delivered after such applicable [***] date. The Price shall be adjusted based on any increase or decrease in the [***] over the previous [***] (the “[***] Price Adjustment”), provided that any such
increase or decrease is supported by documentation reasonably satisfactory to the other Party evidencing such [***] Price Adjustment; and provided further that the [***] Price Adjustment shall not exceed [***] percent ([***]%) of the average price
per kilogram paid by OREXIGEN for purchases made in the previous [***]. The Price shall also be adjusted [***] based on the percent increase or decrease in the [***] measured over the previous [***] (the “[***] Adjustment”),
provided that any such increase or decrease is supported by documentation reasonably satisfactory to the other Party evidencing such [***] Adjustment. CILAG and OREXIGEN, as applicable, shall be entitled to adjust the Price at any time during the
term of this Agreement (to take effect for Purchase Orders accepted after the date of such adjustment) by 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	 
giving [***] ([***]) days prior written notice to the other Party solely to take into account any documented and verifiable increases or decreases in the
[***] resulting from (i) [***] (“[***] Price Change”), or (ii) changes in [***] or [***] (other than as a result of [***] or any changes to [***] (“[***] Price Change”). In the event of (i) a [***]
Price Change, CILAG and OREXIGEN shall negotiate in good faith to adjust the Price based on the changes to the [***], and (ii) a [***] Price Change, the Price shall be increased by an amount equal to [***] percent ([***]%) of [***] Price
Change, provided that in either case, if the applicable change results in an increase in the Price payable by OREXIGEN and OREXIGEN disagrees with CILAG that the [***] changes are necessary [***], then OREXIGEN shall, within [***] ([***]) days of
receipt of such notice from CILAG, notify CILAG in writing of OREXIGEN’s disagreement and the rationale for such disagreement. The Parties shall thereafter attempt in good faith to agree upon whether such change is necessary and who shall bear
the costs due to such change by negotiation and consultation between appropriate representatives of each of the Parties. In the event said representatives are unable to reach a consensus within [***] ([***]) days, such dispute shall be resolved in
accordance with Section 13.3. 

  

	5.4.	If at any time during the term, [***]. 

  

	5.5.	If at any time on or after the [***]. 

  

	    	[***]. 

  

	5.6.	CILAG agrees to keep full, clear and accurate books and records with respect to costs of commercial manufacture of Naltrexone Hydrochloride for a minimum period of [***] ([***])
years after the calendar year in which they are prepared, or for such longer period as may be required by Applicable Law. OREXIGEN shall have the right to have a third party independent external auditor conduct an audit of CILAG’s books and
records for the purpose of verifying any Price adjustments made pursuant to this Section 5.3, 5.4 or 5.5 If so requested by OREXIGEN, such independent external auditor shall provide written confirmation of the accuracy of any Price adjustments
in Sections 5.3, 5.4 or 5.5 prior to the implementation of such Price adjustments. If the independent external auditor is unable to confirm such Price adjustments, the Price [***]. The final report of the independent external auditor shall be shared
with both of the Parties. Any amounts that are determined to be due and owing by one Party to the other Party following such audit shall be paid within [***] ([***]) days thereafter. OREXIGEN shall bear the cost of such audit The Parties shall
cooperate with one another in good faith to resolve any disputes concerning the auditor’s conclusions in accordance with Section 13.3. 

  

	5.7.	CILAG shall issue its invoice to OREXIGEN at the time of shipment. Each invoice shall set forth the applicable Price for the shipment properly determined in accordance with the
provisions of this Agreement. Payment of the invoice by OREXIGEN shall be within [***] ([***]) days following receipt of such invoice. Payment shall be subject to the inspection and acceptance procedures set forth in Section 6. OREXIGEN may
withhold a portion of any invoice that it disputes in good faith pending resolution of such dispute. All invoices and payments shall be in U.S. Dollars. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	6.	INSPECTION OF SHIPMENTS 

  

	6.1.	OREXIGEN shall visually inspect or have visually inspected the Naltrexone Hydrochloride delivered hereunder for obvious damage, failure to meet Specifications and/or shortage
(collectively, “Obvious Damage”) after receipt thereof and shall provide CILAG with written notice of any such Obvious Damage within [***] ([***]) days after receipt. OREXIGEN shall be deemed to have accepted any shipment of
Naltrexone Hydrochloride, but only with respect to Obvious Damage, unless CILAG receives the written notice required within the [***] ([***])-day time period specified above. At its discretion, OREXIGEN may also test, or have tested, any lot of
Naltrexone Hydrochloride supplied to OREXIGEN. 

  

	6.2.	At any time within [***] ([***]) months after receipt of any lot of Naltrexone Hydrochloride but promptly after discovery, OREXIGEN may provide CILAG with written notice of any
non-obvious damage, including adulteration of the Naltrexone Hydrochloride, failure to meet Specifications, or other latent damage or defect (collectively, “Non-Obvious Damage”). Obvious Damage and Non-Obvious Damage shall
hereinafter be collectively referred to as “Damage.” OREXIGEN may reject any portion of any shipment of Naltrexone Hydrochloride which contains any Damage by providing written notice to CILAG of its rejection. OREXIGEN agrees to
provide CILAG’s Quality Control Department with documentation of Damage to confirm the existence thereof in connection with any notice of rejection 

  

	6.3.	If CILAG and OREXIGEN disagree as to the existence of Damage, then they will diligently and in good faith repeat the analyses of samples from the shipment in question and implement
suitable controls to determine the source of the discrepancy in results and the cause of any detected Damage, applying all objective and sound principles of scientific investigation. If after such repeated analyses CILAG and OREXIGEN continue to
disagree, they will then submit representative samples of the shipment to a mutually acceptable independent testing lab and the results of said lab shall be binding on CILAG and OREXIGEN. The costs associated with such submission shall be borne by
the Party against which the lab decided. 

  

	6.4.	 Provided OREXIGEN provides notice of the damage claimed within [***] ([***]) days of receipt of the allegedly Damaged Naltrexone Hydrochloride, in the case of
Obvious Damage, and within [***] ([***]) months of receipt of the allegedly Damaged Naltrexone Hydrochloride in the case of Non-Obvious Damage, whether or not CILAG accepts OREXIGEN’s basis for rejection, CILAG shall promptly, on receipt of a
notice of rejection and its prompt verification of the Damage and/or shortage, at OREXIGEN’s request and at no additional cost to OREXIGEN (including, without limitation, the cost of transportation, export or import duties, if any, taxes,
insurance and handling costs), deliver to OREXIGEN quantities of replacement Naltrexone Hydrochloride equal to the rejected or short quantities as soon as reasonably practicable thereafter, and in no event more than [***] ([***]) days after such
notice is given and OREXIGEN shall have no obligation to pay for 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	 
such Naltrexone Hydrochloride until such time as conforming replacement Naltrexone Hydrochloride has been received. CILAG will use expedited means of
transport, if so requested by OREXIGEN at OREXIGEN’s expense unless such Naltrexone Hydrochloride being replaced is determined to have been Damaged. 

  

	6.5.	Notwithstanding any other provisions of this Agreement, OREXIGEN agrees, if so requested by CILAG, to return to CILAG, at CILAG’s expense, any Naltrexone Hydrochloride that is
deemed to be Damaged pursuant to this Section 6, or otherwise to dispose of such Naltrexone Hydrochloride as CILAG may request. 

  

	7.	CONFIDENTIALITY 

  

	7.1.	During the term of this Agreement, the Parties may disclose certain confidential and proprietary information and data to each other relating to their respective products, including
active pharmaceutical ingredients and Finished Products (“Products”) and businesses, including, but not limited to financial and other business information, Product samples, formulas, manufacturing processes, specifications,
drawings, schematics and other technical, customer and Product development plans, forecasts, strategies and other data. Except as otherwise specifically provided herein, all information disclosed by one Party (in such capacity, the
“Disclosing Party”) to the other Party (in such capacity, the “Receiving Party”) relating to the Disclosing Party’s Products and/or its business operations and the results, reports, etc., of testing and
evaluation of any such information shall constitute “Proprietary Information.” 

  

	7.2.	Proprietary Information disclosed by a Disclosing Party to a Receiving Party hereunder shall be used by the Receiving Party solely in connection with exercising its rights or
performing its obligations under this Agreement. 

  

	7.3.	In consideration of the Disclosing Party’s disclosure and supply of Proprietary Information, each Party, as a potential Receiving Party, agrees that, for the term of the
Agreement and for a period of [***] ([***]) years thereafter, it shall use the Disclosing Party’s Proprietary Information exclusively to conduct the activities contemplated under this Agreement. Each Party further agrees, as a potential
Receiving Party, for the term of the Agreement and for a period of [***] ([***]) years thereafter, it shall not disclose, without the express written consent of the Disclosing Party, any Proprietary Information, including this Agreement or the
interest of the Disclosing Party in exploring the possibility of entering into a business relationship with the Receiving Party, to any person other than to those employees, consultants or agents of the Receiving Party
(“Representatives”) who will be directly involved in fulfilling the Receiving Party’s obligations under this Agreement, provided that such Representatives have assumed like obligations of confidentiality in writing to the
Disclosing Party. Notwithstanding the foregoing, (a) OREXIGEN may disclose the existence and terms of this Agreement to bona fide potential investors, acquirers, corporate partners and financial advisors and (b) CILAG may disclose the
existence (but not the terms of) this Agreement to bona fide potential investors and financial advisors. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	7.4.	Each Party, as a potential Receiving Party, agrees to advise those of its Representatives who receive Proprietary Information (and such other persons who may receive Proprietary
Information as permitted by 7.3(a) or 7.3(b) above) that such information (a) is proprietary and confidential to the Disclosing Party and (b) shall not be disclosed to anyone except as authorized herein. Each Party further agrees to take
such reasonable precautions as it normally takes with its own confidential and proprietary information to prevent unauthorized disclosure or use of such Proprietary Information. 

  

	7.5.	In the event that the Receiving Party is required by any government regulation, law, court order or rule or otherwise becomes legally compelled to disclose any Proprietary
Information, it will provide the Disclosing Party with prompt advance notice in writing so that the Disclosing Party may, at its discretion, reasonably intervene prior to disclosure. The Receiving Party will exercise its commercially reasonable
efforts to obtain reliable assurance that confidential treatment will be accorded to such Proprietary Information. 

  

	7.6.	Notwithstanding any of the foregoing, the term “Proprietary Information” and the obligation of confidentiality associated therewith shall not apply to the following
information: (a) information which, at the time of the Disclosing Party’s disclosure to the Receiving Party, is publicly known; (b) information which, after the Disclosing Party’s disclosure to the Receiving Party, becomes
publicly known, except where such knowledge is the result of the Receiving Party’s breach of this Agreement or otherwise is the result of any unauthorized disclosure by any of its employees or Representatives; (c) information which, prior
to the Disclosing Party’s disclosure to the Receiving Party, was already in the Receiving Party’s possession, as evidenced by its prior written records; or (d) information which, subsequent to the Disclosing Party’s disclosure to
the Receiving Party, is obtained by the Receiving Party from a third Party which is lawfully in possession of such information and not subject to a contractual or fiduciary relationship to the Disclosing Party with respect thereto.

  

	7.7.	Upon the termination of this Agreement, the Receiving Party shall, if so requested by the Disclosing Party, promptly return to the Disclosing Party the originals and all copies of
any Proprietary Information then in the Receiving Party’s possession. Notwithstanding the foregoing, Receiving Party may retain one copy of such Proprietary Information for archival purposes. 

  

	8.	QUALITY OF NALTREXONE HYDROCHLORIDE; REGULATORY MATTERS; REPRESENTATIONS
AND WARRANTIES 

  

	8.1.	CILAG hereby represents, warrants and covenants as follows: 

  

	 	8.1.1.	 At all times during the term of this Agreement, CILAG’s facilities shall remain in compliance with, and the Naltrexone Hydrochloride shall be manufactured and
delivered in compliance with, all applicable laws, regulations and standards, including but not limited to, the provisions of the Federal Food, Drug, and Cosmetic Act, as amended from time to time (the “Act”); the FDA’s cGMP,
including the FDA’s Guidance for Industry, Manufacturing, Processing or Holding Active Pharmaceutical Ingredients, March 1998, and any updates thereto; the FDA’s 

	 	 
regulations for drug establishment registration; the Specifications; the other rules and regulations promulgated under the Act relating to the manufacture of
pharmaceutical products; and equivalent laws, regulations and standards promulgated by Regulatory Agencies in all jurisdictions for which OREXIGEN has given notice to CILAG (collectively, the “Applicable Laws”).

  

	 	8.1.2.	No Naltrexone Hydrochloride constituting or being a part of any shipment to OREXIGEN shall at the time of any such shipment be adulterated within the meaning of the Act, or the
rules and regulations promulgated thereunder, as such law, rule or regulation is constituted and in effect at the time of any such shipment. 

  

	 	8.1.3.	All Naltrexone Hydrochloride supplied to OREXIGEN hereunder (i) shall comply with the Specifications; (ii) shall have been manufactured, stored and shipped in accordance
with the Specifications, applicable approvals from Regulatory Agencies and all Applicable Laws, (iii) may be introduced into public commerce consistent with the intended use for Naltrexone Hydrochloride pursuant to Applicable Laws, and
(iv) will have expiration dating of not less than two thirds of the applicable expiration dating from the date of delivery in accordance with this Agreement. 

  

	 	8.1.4.	All necessary licenses, permits or approvals required by Applicable Laws in connection with the manufacture, storage, and shipment of Naltrexone Hydrochloride hereunder, including
without limitation permits related to manufacturing facilities shall be obtained and maintained. 

  

	 	8.1.5.	CILAG will (i) respond fully and accurately to all inquiries directed to it by the FDA or any other Regulatory Agency that may impact the quality or timely delivery of
Naltrexone Hydrochloride and promptly notify OREXIGEN of same, (ii) assist OREXIGEN in responding to inquiries directed to OREXIGEN by the FDA or other Regulatory Agencies, and (iii) provide the FDA or other Regulatory Agencies with such
information and data as is requested by the FDA or other Regulatory Agencies with respect to the manufacture, use, route of synthesis and testing of the Naltrexone Hydrochloride. 

  

	 	8.1.6.	CILAG’s manufacturing facilities are, and shall at all times during the term of this Agreement be, in compliance with the FDA’s cGMP. 

	 	8.1.7.	CILAG has disclosed to OREXIGEN an accurate summary of all warning letters or similar notices relating to its manufacturing facilities or import alerts (including FDA Form
483’s), if any, for products manufactured in its facilities issued during the last five (5) years and will during the term disclose in timely fashion an accurate summary of such letters, alerts and notices, 

  

	 	8.1.8.	CILAG has, and shall maintain, sufficient facilities, personnel and resources to meet its obligations to supply Naltrexone Hydrochloride under this Agreement.

  

	 	8.1.9.	CILAG is not aware of any claim by a third party that the Naltrexone Hydrochloride supplied hereunder or its process for manufacturing the Naltrexone Hydrochloride supplied
hereunder would, if carried out in the United States or in any other country where generic Naltrexone Hydrochloride is manufactured or sold, infringe, misappropriate or violate any patent, trade secret or other intellectual property right in effect
in such countries. 

  

	 	8.1.10.	To CILAG’s knowledge ([***]), the Naltrexone Hydrochloride supplied to OREXIGEN under this Agreement and CILAG’s process for manufacturing the Naltrexone Hydrochloride
supplied hereunder will not infringe, misappropriate or violate any patent, trade secret or other intellectual property right in effect during the term of this Agreement in the United States. 

  

	 	8.1.11.	There are no pending or threatened claims against CILAG asserting that any of the activities of CILAG relating to the manufacture, import, use and sale of Naltrexone Hydrochloride
in the United States or the conduct of the activities contemplated herein by OREXIGEN, infringe, misappropriate or violate the rights of any third party. 

  

	8.2.	OREXIGEN hereby represents, warrants and covenants that, to OREXIGEN’s knowledge (after reasonable inquiry and investigation), the Finished Product will not infringe,
misappropriate or violate any third party patent, trade secret or other intellectual property right in effect during the term of this Agreement in the United States (provided, that OREXIGEN’s representation does not extend to any infringement,
misappropriation or violation that arises out of or relates to the Naltrexone Hydrochloride or the process for manufacturing the Naltrexone Hydrochloride). 

  

	8.3.	Each Party represents and warrants that all corporate action on its part and on the part of each of its officers and directors necessary for the authorization, execution and
delivery of this Agreement has been taken, it has the full right and authority to enter into this Agreement and perform its obligations hereunder and that it is not aware of any obligations owed to third parties that would conflict with its ability
to perform its obligations hereunder. 

  

	8.4.	If requested in writing by OREXIGEN, CILAG shall permit OREXIGEN or its authorized representatives to inspect CILAG’s facilities and records and be given access to CILAG’s
personnel (at reasonable times, upon reasonable advance notice and in the company of a CILAG representative during normal business hours), to the extent OREXIGEN deems reasonably necessary to enable OREXIGEN to verify compliance by CILAG with its
obligations under this Agreement and to verify compliance with any Applicable Laws. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	8.5.	CILAG shall provide upon request by OREXIGEN confirmation that it has timely filed with the FDA and all other relevant Regulatory Agencies, any required DMF-related filings.

  

	8.6.	OREXIGEN shall provide CILAG copies of product complaints, or notices or inquiries from the FDA or other Regulatory Agencies, which raise issues with respect to the manufacture or
product quality of the Naltrexone Hydrochloride provided by CILAG to OREXIGEN. CILAG shall fully and appropriately investigate such matters and provide OREXIGEN with a report of its investigation. In the event that CILAG receives any complaint,
claims or adverse reaction reports regarding Naltrexone Hydrochloride, including notices from the FDA regarding any alleged regulatory noncompliance of Naltrexone Hydrochloride, CILAG shall promptly and not more than [***] ([***]) business days
after receipt, provide to OREXIGEN all information contained in the complaint, report or notice and such additional information regarding Naltrexone Hydrochloride as OREXIGEN may reasonably request. CILAG shall comply, at a minimum, with FDA
requirements for complaint handling with respect to such complaints, claims or adverse reaction reports. 

  

	8.7.	OREXIGEN and CILAG each further represents and warrants, for itself, that it shall comply with all Applicable Laws in the performance of its obligations hereunder.

  

	8.8.	CILAG shall promptly notify OREXIGEN of any problems or unusual production situations which have, or are reasonably likely to have, an adverse effect on CILAG’s ability to
perform its obligations hereunder or to deliver the Naltrexone Hydrochloride to OREXIGEN in a timely manner. CILAG will make its facilities available for inspection by representatives of any Regulatory Agency in compliance with all Applicable Laws.
In addition, CILAG shall notify and, if applicable, provide copies of any notices or communications to, OREXIGEN of any FDA or other Regulatory Agency inspection, investigation or other inquiry or communication relating to the manufacture of the
Naltrexone Hydrochloride promptly and not more than [***] ([***]) business days after CILAG becomes aware of such inspection, investigation or other inquiry or communication. To the extent such inspection, investigation or other inquiry concerns
Naltrexone Hydrochloride, CILAG shall promptly thereafter provide to OREXIGEN a written summary of all findings and corrective actions taken or planned by CILAG, including any written responses from CILAG to the FDA or other Regulatory Agency. CILAG
shall also discuss with OREXIGEN any response to observations and notifications received in connection with any inspection, investigation, communication or other inquiry concerning Naltrexone Hydrochloride and will give OREXIGEN an opportunity to
comment upon any proposed response before it is made. Any notices under this Section 8.8 shall not operate to relieve CILAG of its obligations to deliver the ordered amounts of Naltrexone Hydrochloride or affect OREXIGEN’s right to pursue
any remedies that might be available to it. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	8.9.	CILAG covenants that it will not in the performance of its obligations under this Agreement use the services of any person debarred or suspended under 21 U.S.C. §35(a) or (b).
CILAG represents that it does not currently have, and covenants that it will not hire, as an officer or an employee, any person who has been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug
product under the Act. 

  

	8.10.	CILAG shall maintain commercial general liability insurance and product liability insurance with a minimum limit per occurrence or accident of $[***] and an annual aggregate limit
of $[***] for the term of this Agreement and for [***] ([***]) years thereafter. Upon request, CILAG will provide to OREXIGEN copies of insurance certificates reflecting the above. 

  

	8.11.	CILAG shall immediately notify OREXIGEN of any information of the following kind about Naltrexone Hydrochloride provided to OREXIGEN: 

  

	 	8.11.1.	information indicating that shipped product has not been manufactured or supplied in accordance with the Specifications, cGMP, this Agreement or in compliance with Applicable Laws;
and 

  

	 	8.11.2.	information concerning any bacteriological contamination, or any significant chemical, physical or other changes or deterioration in the shipped Naltrexone Hydrochloride, or the
failure of one or more shipped lots of Naltrexone Hydrochloride to meet Specifications, including stability parameters. 

  

	8.12.	Without limiting the foregoing, the Parties shall enter into a Quality Agreement within six (6) months of the date of the execution of this Agreement (the “Quality
Agreement”). In the event there is any conflict in the terms and provisions of this Agreement and the Quality Agreement, the terms and provisions of this Agreement shall control and prevail. 

  

	8.13.	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NO PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

	9.	INDEMNIFICATION 

  

	9.1.	OREXIGEN hereby agrees to and shall defend, indemnify, and hold harmless CILAG, its affiliates and each of their respective employees, officers, directors and agents (the
“Supplier Indemnitees”), from, against, and in respect of, any and all losses, judgments, damages, liabilities, suits, actions, expenses (including reasonable attorney’s fees), and proceedings arising from any claims of any
third party to the extent resulting from: 

  

	 	9.1.1.	any misrepresentation, breach of warranty, or the non-fulfillment of any obligation, covenant, or duty on the part of OREXIGEN under this Agreement; 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	9.1.2.	any claim, complaint, suit, proceeding or cause of action against any of the Supplier Indemnitees alleging physical injury or death, brought by or on behalf of an injured party, or
loss of service or consortium or a similar such claim, complaint, suit, proceeding or cause of action brought by a spouse, relative or companion of an injured party due to such physical injury or death, and in each case arising out of the Finished
Products; 

  

	 	9.1.3.	any negligence or willful misconduct of OREXIGEN, its employees, officers and directors in performing this Agreement; and 

  

	 	9.1.4.	any claim of patent infringement relating to a Finished Product or the process for manufacturing a Finished Product (excluding any claim of patent infringement arising out of or
relating to the Naltrexone Hydrochloride or the process for manufacturing the Naltrexone Hydrochloride), which claim, if true, would be in contravention of the representations, warranties and covenants of OREXIGEN hereunder;

 except to the extent resulting from (i) any misrepresentation, breach of warranty, or the non-fulfillment of any
obligation, covenant, or duty on the part of CILAG under this Agreement, (ii) any negligence or willful misconduct of the Supplier Indemnitees in performing this Agreement, or (iii) any claim subject to CILAG’s indemnification
obligations under Section 9.2. 
  

	9.2.	CILAG hereby agrees to and shall defend, indemnify, and hold harmless OREXIGEN, its affiliates and each of their respective employees, officers, directors and agents (the
“OREXIGEN Indemnitees”), from, against, and in respect of, any and all losses, judgments, damages, liabilities, suits, actions, expenses (including reasonable attorney’s fees), and proceedings arising from any claims of any
third party to the extent resulting from: 

  

	 	9.2.1.	any misrepresentation, breach of warranty, or the nonfulfillment of any obligation, covenant, or duty on the part of CILAG under this Agreement; 

  

	 	9.2.2.	any claim, complaint, suit proceeding or cause of action against any of the OREXIGEN Indemnitees alleging physical injury or death, brought by or on behalf of an injured party, or
loss of service or consortium or a similar such claim, complaint, suit, proceeding or cause of action brought by a spouse, relative or companion of an injured party due to such physical injury or death, and in each case arising because Naltrexone
Hydrochloride supplied by CILAG to OREXIGEN did not meet the warranties in Section 8.1. 

  

	 	9.2.3.	any negligence or willful misconduct of CILAG or its employees, officers or directors in performing this Agreement; and 

	 	9.2.4.	any claim of patent infringement relating to the Naltrexone Hydrochloride supplied to OREXIGEN or the process for manufacturing the Naltrexone Hydrochloride supplied to OREXIGEN
which claim, if true, would be in contravention of the representations, warranties and covenants of CILAG hereunder; 

 except
to the extent resulting from (i) any misrepresentation, breach of warranty, or the non-fulfillment of any obligation, covenant, or duty on the part of OREXIGEN under this Agreement, (ii) any negligence or willful misconduct of the OREXIGEN
Indemnitees in performing this Agreement, or (iii) any claim subject to OREXIGEN’s indemnification obligations under Section 9.1. 
  

	9.3.	 The foregoing indemnification obligations are subject to the following: (a) the indemnifying Party must be notified by or on behalf of the indemnified Party in
writing promptly after a claim is made, a suit is filed or an action or investigation is initiated (each, a “Proceeding”) against the indemnified Party, unless such delay does not materially prejudice the indemnifying Party;
(b) subject to the provisions set forth below in this Section 9.3, the indemnifying Party shall be permitted to defend, control, conduct and prosecute, in the indemnifying Party’s sole discretion and by counsel of the indemnifying
Party’s choosing, the defense of such Proceeding brought against the indemnified Party; (c) the indemnifying Party shall have the right in its sole discretion to settle, compromise or otherwise terminate the Proceeding solely upon the
payment of money; provided, that, there is no finding or admission of any violation by any indemnified Party of (i) any law, rule or regulation or (ii) the rights of any person; and provided, further, that, no such settlement shall
prohibit any indemnified Party from importing the Naltrexone Hydrochloride into the United States or making, using or selling products in the United States made from such Naltrexone Hydrochloride; (d) the indemnified Party shall refrain from
settling (or endeavoring to settle, or entering into settlement negotiations with respect to) any such Proceeding without the indemnifying Party’s prior written consent; (e) except as may otherwise be required by law, the indemnified Party
shall not compromise the position of the indemnifying Party by admission, statements, disclosure or conduct (collectively, “Disclosure”) in a way that could prejudice the defense, control, conduct or prosecution of said cause of
action (it being understood that no indemnified Party shall be deemed to have violated this provision so long as such Party has acted in good faith to fulfill its obligations under this provision); and (f) the indemnified Party shall cooperate
with the indemnifying Party in the defense, conduct, prosecution or termination of the Proceeding, including the furnishing of information and the assistance from employees of the indemnified Party at the indemnifying Party’s reasonable request
and expense. With respect to clause (e) above, the indemnified Party will provide the indemnifying Party with prompt written notice in advance of any such Disclosure being made to permit the indemnifying Party to seek an appropriate protective
order, restriction on response or withdrawal of the request for Disclosure. If, however, any such request for relief by the indemnifying Party is denied or is otherwise unavailable, the relevant indemnified Party may make the Disclosure without any
liability to the indemnifying Party. The indemnified Party may, at its option and expense, participate in the indemnifying Party’s defense with counsel of its own choosing, and if the indemnified Party so participates, the Parties shall
cooperate with one another in such defense in a commercially reasonable 

	 	 
fashion. Notwithstanding any provision in this Agreement to the contrary, OREXIGEN shall at all times have the right to assume direction and control of the
defense of any claim alleging infringement, misappropriation or violation of any patent, trade secret or other intellectual property right of any third party, provided that OREXIGEN will provide CILAG with a reasonable opportunity to review and
consult from time to time concerning the strategy and action plan (including possibly pursuing one or more licenses as appropriate), and in such event CILAG shall cooperate and assist as requested in the defense of such claim and if OREXIGEN finds
it necessary or desirable to join CILAG as a party, CILAG shall execute all papers or perform such other acts as may reasonably be required by OREXIGEN. Further, CILAG shall not settle or consent to the entry of any judgment with respect to any such
claim, without OREXIGEN’s prior written consent. 

  

	9.4.	The indemnification rights provided for herein are in addition to, and not in substitution for, any and all remedies available to a Party under this Agreement or otherwise at law or
in equity. Notwithstanding anything to the contrary in this Section 9, each Party may, and expressly reserves the right to, seek judicial relief from any court of competent jurisdiction in order to obtain an injunction or other equitable
relief. 

  

	9.5.	IN NO EVENT SHALL ANY OF THE PARTIES HERETO BE RESPONSIBLE OR LIABLE TO THE OTHER UNDER ANY PROVISION OF THIS AGREEMENT OR UNDER ANY THEORY OF NEGLIGENCE, STRICT LIABILITY OR OTHER
LEGAL OR EQUITABLE THEORY, FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, OR EXEMPLARY DAMAGES OR LOST PROFITS. FOR THE PURPOSE OF CLARITY, NOTHING IN THIS SECTION IS INTENDED TO LIMIT THE INDEMNIFICATION OBLIGATIONS OF ANY PARTY WITH RESPECT TO THE
CHARACTERIZATION OF ANY CLAIM BY A THIRD PARTY AS CONSEQUENTIAL, INDIRECT, SPECIAL, OR EXEMPLARY DAMAGES OR LOST PROFITS. 

	10.	ADVERSE EVENT REPORTING; COSTS AND EXPENSES OF RECALL 

  

	10.1.	OREXIGEN shall have sole control and responsibility for reporting all adverse events associated with the use of Finished Products in humans, whether expected or unexpected and
whether or not considered drug related, including the following: (i) an adverse event occurring in the course of the use of a drug product in professional practice; (ii) an adverse event occurring from drug overdose whether accidental or
intentional; (iii) an adverse event occurring from drug abuse; or (iv) an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action (collectively, “Adverse Events”), with respect to
the Finished Products, and responding to all Finished Product quality complaints and medical and technical inquiries, whether from lay persons, health care professionals and or Regulatory Agencies. Notwithstanding the foregoing, to the extent CILAG
has an obligation to report any Adverse Events to any Regulatory Agencies it may do so provided it first provides written notice to OREXIGEN thereof and a copy of such report. CILAG agrees to consider in good faith any comments OREXIGEN has timely
provided concerning such reports prior to CILAG’s submission of the same to the applicable Regulatory Agency. In the event CILAG (a) receives any information regarding any Adverse Event relating to Naltrexone Hydrochloride or any Finished
Products or their manufacture, (b) receives any complaints relating, or potentially relating, to Naltrexone Hydrochloride or any Finished Products or their manufacture, (c) receives any medical or technical inquiry relating, or potentially
relating, to Naltrexone Hydrochloride or any Finished Products or their manufacture, or (d) discovers or is notified of any material defect in Naltrexone Hydrochloride or any Finished Products, it shall (i) notify OREXIGEN within [***]
([***]) days thereof, and (ii) promptly conduct an investigation in accordance with its approved written procedures for the surveillance, receipt, evaluation, and reporting of complaints, inquiries or discoveries of that nature and report the
results of such investigation to OREXIGEN promptly upon the completion thereof. 

  

	10.2.	OREXIGEN shall have sole control and responsibility for conducting all voluntary and involuntary recalls or other related action (collectively, “Recalls”) of units
of any Finished Product; provided, however, that CILAG agrees to reimburse OREXIGEN for all of its reasonable costs and expenses incurred with respect to any Recalls arising out of any of the causes set forth in Sections 9.2.1 through 9.2.4.
Further, in the event of any Recall of any Finished Products arising out of any of the causes set forth in Sections 9.2.1 through 9.2.4, OREXIGEN’s obligation to pay CILAG for Naltrexone Hydrochloride purchased hereunder shall cease. This
Section 10 is intended to augment and not limit the indemnification provisions of Section 9 herein. 

  

	11.	TERM AND TERMINATION 

  

	11.1.	This Agreement shall commence on the Effective Date and shall continue in effect until the date that is four (4) years from the Qualification Date (the “Initial
Term”), unless earlier terminated or extended in accordance with it terms. At least one year prior to the expiration of the Initial Term the Parties shall discuss the terms of the renewal term. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	11.2.	This Agreement may be terminated by (i) OREXIGEN upon [***] ([***]) days written notice to CILAG of a failure by CILAG to perform or observe any material covenant, condition or
agreement to be performed or observed by it under this Agreement, unless such breach has been cured within the [***] ([***]) day notice period, and (ii) CILAG upon [***] ([***]) days written notice to OREXIGEN of a failure by OREXIGEN to
perform or observe any material covenant, condition or agreement to be performed or observed by it under this Agreement, unless such breach has been cured within the [***] ([***]) day notice period; provided, that if the breach by OREXIGEN is a
failure to pay an invoice when due (except as provided in Section 5.8), then the notice and cure period shall be [***] ([***]) days. 

  

	11.3.	OREXIGEN may terminate this Agreement effective immediately upon written notice to CILAG in the event that (a) CILAG dissolves, is declared insolvent or bankrupt by a court of
competent jurisdiction; (b) a voluntary or involuntary petition of bankruptcy is filed in any court of competent jurisdiction by CILAG; or (c) this Agreement is assigned by CILAG for the benefit of creditors. CILAG may terminate this
Agreement effective immediately upon written notice to OREXIGEN in the event that (a) OREXIGEN dissolves, is declared insolvent or bankrupt by a court of competent jurisdiction; (b) a voluntary or involuntary petition of bankruptcy is
filed in any court of competent jurisdiction by OREXIGEN; or (c) this Agreement is assigned by OREXIGEN for the benefit of creditors. 

  

	11.4.	OREXIGEN may terminate this Agreement effective immediately upon written notice to CILAG in the event that (a) any Regulatory Agency takes any action, or raises any objection,
that prevents OREXIGEN from importing, exporting, purchasing or selling either the Naltrexone Hydrochloride or the Finished Product; (b) the Finished Product fails during clinical trials and OREXIGEN withdraws its NDA; (c) OREXIGEN
determines, in its sole discretion, to no longer pursue the development and/or commercialization of a Finished Product which contains Naltrexone Hydrochloride; or (d) a legal proceeding shall be instituted against CILAG, which is reasonably
likely to materially adversely affect CILAG’s ability to properly perform under this Agreement or subject OREXIGEN to any material risk of liability or loss. 

  

	11.5.	In the event of termination of this Agreement by OREXIGEN pursuant to Section 11.4, OREXIGEN agrees to pay for previously placed orders of Naltrexone Hydrochloride but not yet
delivered to OREXIGEN, provided that CILAG shall use reasonable commercial efforts to mitigate the amount of such payments by OREXIGEN, including, but not limited to, selling such Naltrexone Hydrochloride to other customers, and provided further
that CILAG shall deliver Naltrexone Hydrochloride pursuant to such orders in accordance with this Agreement. 

  

	11.6.	The provisions of this Section 11 as to termination shall not limit or restrict the rights of any Party to seek remedies or take measures that may be otherwise available to it
at law or equity in connection with the enforcement and performance of obligations under this Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	12.	NOTICES 

 Any and all notices required to be given
under this Agreement will be in writing and effective upon receipt, sent by facsimile transmission, mailed postage prepaid by first-class certified or registered mail, or sent by express courier service, at the respective addresses, as follows:

 IF TO OREXIGEN, TO: 
 Orexigen
Therapeutics, Inc. 
 3344 N. Torrey Pines Court 
 Suite 200 
 La Jolla, CA 92037 
 Attention: Vice President of Technical Operations 
 Telephone Number: (858) 875-8600 
 Facsimile Number: (858) 875-8650 
 With a copy to:

 Orexigen Therapeutics, Inc. 
 3344 N. Torrey Pines Court 
 Suite 200 
 La Jolla, CA 92037 
 Attention: General Counsel 
 Telephone Number: (858) 875-8600 
 Facsimile Number: (858) 875-8650 
 With an additional copy to (which shall not by itself constitute notice): 
 Latham & Watkins LLP 
 12636 High
Bluff Drive, Suite 400 
 San Diego, CA 92130 
 Attention: Cheston J. Larson, Esq. 
 Telephone Number: (858) 523-5400 
 Facsimile Number: (858) 523-5450 
 IF TO CILAG,
TO: 
 Cilag AG 
 Hochstrasse
201 
 8205 Schaffhaussen 
 Attention: General Manager Allied Business 
 Telephone Number: (052) 630-91-11 
 Facsimile Number: (052) 630-94-43 

 With a copy to: 
 Cilag AG 
 Hochstrasse 201 
 8205 SchaffhaussenSwitzerland 
 Attention: [Director Sales & Contract Administration 
 Telephone Number: (052) 630-91-11 
 Facsimile Number: (052) 630-94-43 
  

	13.	MISCELLANEOUS 

  

	13.1.	Force Majeure. In the event that any Party hereto is prevented from complying, either in whole or in part, with any of the terms or provisions of this Agreement by reason of
fire, flood, storm, strike or lockout, riot, war, rebellion, lack or failure of transportation facilities, court order, accident, or Acts of God, and to the extent that the foregoing are beyond a Party’s reasonable control, then, unless
conclusive evidence to the contrary is provided, upon written notice by the Party whose performance is so affected to the other, the requirements of this Agreement so affected (to the extent affected) shall be suspended during the period of, and
only to the extent of, such disability. Said Party shall be excused by reason of said force majeure only so long as it is exercising its best efforts to overcome said reason. Notwithstanding the foregoing, if a force majeure event prevents a
Party’s performance under this Agreement for an aggregate of more than [***] days, the other Party may terminate this Agreement upon written notice to the non-performing Party. 

  

	13.2.	Assurances. Each Party to this Agreement shall execute, acknowledge and deliver such further instruments and documents, and do all such other acts and things as may be
required by law or as may be necessary or advisable to carry out the intents and purposes of this Agreement. The Parties will cooperate with each other and offer reasonable assistance in carrying out their respective responsibilities under this
Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	13.3.	Dispute Resolution. Subject to Section 6.4, any dispute, controversy or claim arising under, out of or in connection with this Agreement, including any subsequent
amendments, or the validity, enforceability, construction, performance or breach thereof (“Dispute”), shall be finally settled under the Rules for Commercial Dispute Resolution Procedures (“Rules”) of the American
Arbitration Association (“AAA”) then in force on the date of commencement of the arbitration by three (3) arbitrators appointed in accordance with those Rules, provided that the arbitrators appointed have at least ten
(10) years arbitration experience in the pharmaceutical industry; provided however if the Parties mutually agree, such arbitration may be conducted by a single mutually agreeable arbitrator. The award rendered shall be final and binding on the
Parties. Judgment upon the award may be entered in any court having jurisdiction. The Parties agree that they will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against either Party. The costs of
any arbitration, including administrative fees and fees of the arbitrators, shall be shared equally by the Parties and each Party shall bear the cost of its own attorneys’ and expert fees, provided that the arbitrator(s) shall have the
discretion, to be exercised in accordance with applicable law, to allocate among the Parties the arbitrators’ fees and litigation costs, and the arbitrator(s) shall also have authority to shift any prevailing Party’s attorney’s fees
to any non-prevailing Party. No Dispute under this Agreement shall be referred to Arbitration under this Section 13.3 until such Dispute has been presented to the respective presidents or senior executives of CILAG and OREXIGEN for their
consideration and resolution. 

  

	13.4.	Governing Law. This Agreement shall be governed by and construed under the laws of the State of California, excluding its conflicts of law provisions.

  

	13.5.	Severability. If any provision of this Agreement shall be held to be invalid, illegal, or unenforceable, the validity, legality, or enforceability of the remaining provisions
hereof shall not in any way be affected or impaired thereby unless the purposes of the Agreement cannot be achieved. In the event any provision shall be held invalid, illegal, or unenforceable the Parties shall use best efforts to substitute a
valid, legal, and enforceable provision which insofar as practical implements the purposes hereof. 

  

	13.6.	No Assignment. No Party shall assign its rights and/or obligations under this Agreement without the prior written consent of the other Parties hereto, except that
(a) OREXIGEN may assign this Agreement in connection with the transfer, license or sale of all or substantially all of its assets or business to which the subject matter of this Agreement relates or in connection with any merger, consolidation
or reorganization, without CILAG’s prior written consent; and (b) CILAG may assign this Agreement in connection with the transfer, license or sale of all or substantially all of its assets or business to which the subject matter of this
Agreement relates or in connection with any merger, consolidation or reorganization with OREXIGEN’s prior written consent, which consent in either case may not be unreasonably withheld. 

  

	13.7.	Waiver. No delay, waiver, omission or forbearance on the part of any Party to exercise any right, option, duty or power arising out of any breach or default by any other
Party of any of the terms, provisions or covenants hereof, will constitute a waiver by such Party of its rights to enforce any such right, option, duties or power as against the other Party hereto, or its rights as to any subsequent breach or
default by the other Party. 

	13.8.	Survival. Upon termination or expiration of this Agreement, the obligations of the Parties which by their nature should survive and the obligations under Sections 7-13 of
this Agreement and under any existing confidentiality agreements between the Parties shall survive. 

  

	13.9.	Entire Agreement. This Agreement and the Schedules and Appendices attached hereto, the confidentiality agreements referenced in Section 13.8, the Quality Agreement and
Purchase Order No. 1153 between the Parties dated January 2, 2008 constitute the full understanding and entire agreement between the Parties and supersede any and all prior oral or written understandings and agreements with respect to the
subject matter hereof. No terms, conditions, understandings, or agreements purporting to modify, amend, waive or terminate this Agreement, or any provision hereof, shall be binding except by the execution of a writing specified to be an explicit
amendment to this Agreement duly executed by the authorized signatories of the Parties hereto. No modification, waiver, termination, rescission, discharge or cancellation of any right or claim under this Agreement shall affect the right of any Party
to enforce any other claim or right hereunder. 

  

	13.10.	Binding Agreement. Subject to Section 13.6, this Agreement shall be binding upon the Parties and their respective successors and permitted assigns and shall insure to
the benefit of the Parties and their respective successors and permitted assigns. 

  

	13.11.	Headings. The headings used in this Agreement are for convenience of reference only and are not a part of the text hereof. 

  

	13.12.	Counterparts. This Agreement may be executed in counterparts, each of which shall constitute an original and all of which shall together constitute a single agreement.

 [Remainder of This Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the Parties hereby agree to the terms and conditions of this Agreement. 
  

													
	OREXIGEN THERAPEUTICS, INC.	 		 	CILAG GMBH INTERNATIONAL	 	
							
	By:	 	/s/ Walter Piskorski	 		 	By:	 	/s/ Heinz Schmid	 		 	/s/ Gilbert Eyer
	Name:	 	Walter Piskorski	 		 	Name:	 	Heinz Schmid	 		 	Gilbert Eyer
	Title:	 	VP Tech. Ops	 		 	Title:	 	General Manager	 		 	Finance Director
					
	Date: January 29, 2009	 		 	Date: January 5, 2009	 		 	
						
	/s/ Graham Cooper	 		 		 		 		 	
	Graham Cooper	 		 		 		 		 	
	Chief Financial Officer	 		 		 		 		 	
					
	1/29/09	 		 		 		 	

 [SIGNATURE PAGE TO NALTREXONE HYDROCHLORIDE SUPPLY AGREEMENT] 

 LIST OF DEFINED TERMS 
  

			
	 DEFINED TERM
	  	SECTION
	 AAA
	  	13.3
	 Act
	  	8.1.1
	 Adverse Events
	  	10.1
	 Agreement
	  	Preamble
	 ANDA
	  	2.3
	 Applicable Laws
	  	8.1.1
	 [***]
	  	5.5
	 cGMP
	  	2.4
	 CILAG
	  	Preamble
	 Commercial Launch
	  	3.2
	 Damage
	  	6.2
	 Disclosing Party
	  	7.1
	 Disclosure
	  	9.3
	 Dispute
	  	13.3
	 DMF
	  	2.1
	 Effective Date
	  	Preamble
	 [***] Adjustment
	  	5.3
	 Exclusivity Obligation
	  	5.1
	 FDA
	  	2.1
	 Finished Products
	  	2.1
	 Firm Commitment
	  	3.1
	 Firm Commitment Purchase Order
	  	3.3
	 [***] Adjustment
	  	5.3
	 Initial Term
	  	11.1
	 NDA
	  	2.3
	 Non-Obvious Damage
	  	6.2
	 Obvious Damage
	  	6.1
	 OREXIGEN
	  	Preamble
	 OREXIGEN Indemnitees
	  	9.2
	 Party
	  	Preamble
	 Parties
	  	Preamble
	 Price
	  	5.2
	 Proceeding
	  	9.3
	 Products
	  	7.1
	 Proprietary Information
	  	7.1
	 Purchase Order
	  	1.2
	 Qualification Date
	  	5.1
	 Quality Agreement
	  	8.12
	 Recalls
	  	10.2
	 Receiving Party
	  	7.1

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

			
	 Regulatory Agency
	  	2.2
	 [***] Price Change
	  	5.4
	 Representatives
	  	7.3
	 Rolling Forecast
	  	3.1
	 Rules
	  	13.3
	 Second-Source Supplier
	  	2.5
	 Specifications
	  	2.1
	 [***] Price Change
	  	5.4
	 Supplier Indemnitees
	  	9.1

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 SCHEDULE A 
 SPECIFICATIONS 
  

					
			
	1	  	[***]	  	[***]
			
	2	  	[***]	  	[***]
	2.1	  	[***]	  	[***]
	2.2	  	[***]	  	
			
	3	  	[***]	  	[***]
			
	4	  	[***]	  	[***]
			
	5	  	[***]	  	[***]
			
	6	  	[***]	  	[***]
			
	7	  	[***]	  	[***]
			
	8	  	[***]	  	[***]
			
	9	  	[***]	  	[***]
			
	10	  	[***]	  	[***]
			
	11	  	[***]	  	[***]
			
	12	  	[***]	  	[***]
			
	13	  	[***]	  	[***]
			
	14	  	[***]	  	[***]
			
	15	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 SCHEDULE B 
 PRICING AND SHIPPING TERMS 
 Freight Terms: CILAG shall make all necessary shipping arrangements
to OREXIGEN’s designated facility, DDP (Incoterms 2000) OREXIGEN’s designated facility, freight prepaid. 
 Shipping Method: Air Freight

 Price: 
 The initial Price, which shall be subject to
adjustment in accordance with Section 5.3, shall be as follows: 
 [***] 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 APPENDIX A 
 FORM OF PURCHASE ORDER

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]